TP53 is the sole mutated gene detected in up to 75% of patients, while patients who harbor co-occurring mutations show a lower incidence of mutations in several AML-related genes such as NPM1, FLT3, IDH1, IDH2, WT1, DNMT3A, RUNX1, and RAS (20, 21). This evidence concerns the gene IDH2 and acute myeloid leukemia.